Beckwith Noor, Reisner Sari L, Zaslow Shayne, Mayer Kenneth H, Keuroghlian Alex S
Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Transgend Health. 2017 Oct 1;2(1):156-164. doi: 10.1089/trgh.2017.0028. eCollection 2017.
Gender-affirming surgeries and hormone therapy are medically necessary treatments to alleviate gender dysphoria; however, significant gaps exist in the research and clinical literature on surgery utilization and age of hormone therapy initiation among transgender adults. We conducted a retrospective review of electronic health record data from a random sample of 201 transgender patients of ages 18-64 years who presented for primary care between July 1, 2010 and June 30, 2015 (inclusive) at an urban community health center in Boston, MA. Fifty percent in our analyses were trans masculine (TM), 50% trans feminine, and 24% reported a genderqueer/nonbinary gender identity. Regression models were fit to assess demographic, gender identity-related, sexual history, and mental health correlates of gender-affirming surgery and of age of hormone therapy initiation. Overall, 95% of patients were prescribed hormones by their primary care provider, and the mean age of initiation of masculinizing or feminizing hormone prescriptions was 31.8 years (SD=11.1). Younger age of initiation of hormone prescriptions was associated with being TM, being a student, identifying as straight/heterosexual, having casual sexual partners, and not having past alcohol use disorder. Approximately one-third (32%) had a documented history of gender-affirming surgery. Factors associated with increased odds of surgery were older age, higher income levels, not identifying as bisexual, and not having a current psychotherapist. This study extends our understanding of prevalence and factors associated with gender-affirming treatments among transgender adults seeking primary care. Findings can inform future interventions to expand delivery of clinical care for transgender patients.
性别肯定手术和激素疗法是缓解性别焦虑症的必要医学治疗方法;然而,关于跨性别成年人的手术利用情况和激素疗法开始年龄的研究及临床文献中存在显著差距。我们对201名年龄在18至64岁之间的跨性别患者的电子健康记录数据进行了回顾性分析,这些患者于2010年7月1日至2015年6月30日(含)在马萨诸塞州波士顿的一家城市社区健康中心接受初级保健。我们分析中的50%为男性跨性别者(TM),50%为女性跨性别者,24%报告有性别酷儿/非二元性别认同。采用回归模型来评估性别肯定手术以及激素疗法开始年龄与人口统计学、性别认同相关、性史和心理健康之间的关联。总体而言,95%的患者由其初级保健提供者开具了激素处方,男性化或女性化激素处方开始的平均年龄为31.8岁(标准差=11.1)。激素处方开始年龄较小与为男性跨性别者、是学生、认定为异性恋、有临时性伴侣以及没有过去的酒精使用障碍有关。大约三分之一(32%)有性别肯定手术的记录史。与手术几率增加相关的因素包括年龄较大、收入水平较高、不认定为双性恋以及没有当前的心理治疗师。这项研究扩展了我们对寻求初级保健的跨性别成年人中性别肯定治疗的患病率及相关因素的理解。研究结果可为未来扩大跨性别患者临床护理提供的干预措施提供参考。